In December 2018, BioNova completed Series A financing with TF Capital and Hillhouse Capital being the lead investors.
In August 2020, BioNova completed Series B financing with OrbiMed and BioTrack Capital being the lead investors.
From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives.
OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made in one of three strategies: public equity, private equity, and private credit/royalty.
Specializes in start-up angel investment for biomedicine and biotechnology professionals. Captures investment opportunities through years of networking and invests in outstanding entrepreneurial teams.
Builds businesses that stand the test of time. Looks for opportunities around the globe, with a focus on Asia, and have the flexibility to work across the equity spectrum, from seed investments to buyouts and listed equities. Deploys technology to drive innovation, with sustainable, long-term growth as the ultimate goal.
Founded in 2008, LAV is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. As a leading biomedical venture fund in China, LAV provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
Founded in 2016, Med-Fine Capital is a VC firm investing in the healthcare and life sciences sectors. Comprised of a team of experienced investors and professionals, Med-Fine Capital provides early stage and fast-growth stage companies with capital, professional expertise and valuable resources.
Mitsui Global Investment (MGI), a 100% subsidiary of Mitsui & Co. Ltd., was established in 1996, with its headquarters in Silicon Valley and branches in Tokyo and Beijing. MGI has been engaging in investments in startups and focus areas covering IT and communication, healthcare and biotech and industrial opportunities. Since its establishment, MGI has invested in and managed over 100 portfolio companies. Our vision is to leverage Mitsui’s global network and provide portfolio companies support to build their business and guide them onto the global stage.
Focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market.